{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:21:26Z","timestamp":1790882486803,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI154546"],"award-info":[{"award-number":["K23AI154546"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as \u22654-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs 10%; P = .002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.<\/jats:p>","DOI":"10.1093\/cid\/ciae332","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T16:08:26Z","timestamp":1718726906000},"page":"24-28","source":"Crossref","is-referenced-by-count":32,"title":["Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant <i>Pseudomonas aeruginosa<\/i> Bacteremia or Pneumonia"],"prefix":"10.1093","volume":"80","author":[{"given":"Sunish","family":"Shah","sequence":"first","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen G","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghady","family":"Haidar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Squires","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K","family":"McCreary","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd G","family":"Clarke","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Stellfox","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Van Tyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]},{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"2025050710271313000_ciae332-B1","doi-asserted-by":"crossref","first-page":"e4521","DOI":"10.1093\/cid\/ciaa1464","article-title":"Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria, 2000\u20132017","volume":"73","author":"Babiker","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025050710271313000_ciae332-B2","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","article-title":"Antibiotic resistance threats in the United States 2019","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2025050710271313000_ciae332-B3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025050710271313000_ciae332-B4","doi-asserted-by":"crossref","first-page":"e0040523","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050710271313000_ciae332-B5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025050710271313000_ciae332-B6","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025050710271313000_ciae332-B7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025050710271313000_ciae332-B8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025050710271313000_ciae332-B9","doi-asserted-by":"crossref","first-page":"e00084-21","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050710271313000_ciae332-B10","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/jac\/dkaa345","article-title":"ResFinder 4.0 for predictions of phenotypes from genotypes","volume":"75","author":"Bortolaia","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025050710271313000_ciae332-B11","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1093\/jac\/dkx217","article-title":"PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens","volume":"72","author":"Zankari","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025050710271313000_ciae332-B12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1471-2105-10-421","article-title":"BLAST+: architecture and applications","volume":"10","author":"Camacho","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2025050710271313000_ciae332-B13","volume-title":"Performance standards for antimicrobial susceptibility testing, M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023","edition":"33rd ed"},{"key":"2025050710271313000_ciae332-B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2025050710271313000_ciae332-B15","doi-asserted-by":"crossref","first-page":"765113","DOI":"10.3389\/fmicb.2021.765113","article-title":"Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa clinical isolates from Saudi Arabia revealed a global dissemination of GES-5-producing ST235 and VIM-2-producing ST233 sub-lineages","volume":"12","author":"Doumith","year":"2022","journal-title":"Front Microbiol"},{"key":"2025050710271313000_ciae332-B16","doi-asserted-by":"crossref","first-page":"e01589-17","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"2025050710271313000_ciae332-B17","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/cid\/ciw829","article-title":"Gram-negative committee of the Antibacterial Resistance Leadership Group (ARLG). Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group","volume":"64","author":"Doi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025050710271313000_ciae332-B18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21\u201322","author":"Oliver","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2025050710271313000_ciae332-B19","doi-asserted-by":"crossref","first-page":"106517","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025050710271313000_ciae332-B20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ijantimicag.2018.01.016","article-title":"Clinical experience with ceftazidime\/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae","volume":"51","author":"Santevecchi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025050710271313000_ciae332-B21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae332\/58516072\/ciae332.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/24\/58516072\/ciae332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/24\/58516072\/ciae332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T14:27:21Z","timestamp":1746628041000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/1\/24\/7696822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,21]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae332","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,6,21]]}}}